Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Oct;81(4):622–630. doi: 10.1038/sj.bjc.6690739

Effects of new 17α-hydroxylase/C17,20-lyase inhibitors on LNCaP prostate cancer cell growth in vitro and in vivo

D N Grigoryev 1, B J Long 1, I P Nnane 1, V C O Njar 1, Y Liu 1, A M H Brodie 1
PMCID: PMC2362906  PMID: 10574247

Abstract

Our laboratory has been developing new inhibitors of a key regulatory enzyme of testicular and adrenal androgen synthesis 17α-hydroxylase/C17,20-lyase (P450c17), with the aim of improving prostate cancer treatment. We designed and evaluated two groups of azolyl steroids: Δ5-non-competitive inhibitors (Δ5NCIs), VN/63-1, VN/85-1, VN/87-1 and their corresponding Δ4 derivatives (Δ4NCIs), VN/107-1, VN/108-1 and VN/109-1. The human P450c17 gene was transfected into LNCaP human prostate cancer cells, and the resultant LNCaP-CYP17 cells were utilized to evaluate the inhibitory potency of the new azolyl steroids. VN/85-1 and VN/108-1 had the lowest IC50 values of 1.25 ± 0.44 nM and 2.96 ± 0.78 nM respectively, which are much lower than that of the known P450 inhibitor ketoconazole (80.7 ± 1.8 nM). To determine whether the compounds had direct actions on proliferation of wild-type LNCaP cells, cell growth studies were performed. All of the Δ5NCIs and VN/108-1 blocked the growth-stimulating effects of androgens. In steroid-free media, the Δ5NCIs decreased the proliferation of LNCaP cells by 35–40%, while all of the Δ4NCIs stimulated LNCaP cells growth 1.5- to 2-fold. In androgen receptor (AR) binding studies, carried out to determine the mechanism of this effect, all of the Δ4NCIs (5 μM) displaced 77–82% of synthetic androgen R1881 (5 nM) from the LNCaP AR. The anti-androgen flutamide and the Δ5NCIs displaced 53% and 32–51% of R1881 bound to AR respectively. These results suggested that the Δ5NCIs may also be acting as anti-androgens. We further evaluated our inhibitors in male severe combined immuno- deficient mice bearing LNCaP tumour xenografts. In this model VN/85-1 was as effective as finasteride at inhibiting tumor growth (26% and 28% inhibition, respectively) and the inhibitory effect of VN/87-1 was similar to that of castration (33% and 36% inhibition respectively). These results suggest that VN/85-1 and VN/87-1 may be potential candidates for treatment of prostate cancer. © 1999 Cancer Research Campaign

Keywords: 17α-hydroxylase/C17,20-lyase inhibitors; azolyl steroids; androgens synthesis; LNCaP cells; SCID mice

Full Text

The Full Text of this article is available as a PDF (207.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Chung B. C., Picado-Leonard J., Haniu M., Bienkowski M., Hall P. F., Shively J. E., Miller W. L. Cytochrome P450c17 (steroid 17 alpha-hydroxylase/17,20 lyase): cloning of human adrenal and testis cDNAs indicates the same gene is expressed in both tissues. Proc Natl Acad Sci U S A. 1987 Jan;84(2):407–411. doi: 10.1073/pnas.84.2.407. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Crawford E. D., Eisenberger M. A., McLeod D. G., Spaulding J. T., Benson R., Dorr F. A., Blumenstein B. A., Davis M. A., Goodman P. J. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 1989 Aug 17;321(7):419–424. doi: 10.1056/NEJM198908173210702. [DOI] [PubMed] [Google Scholar]
  3. Denis L. Role of maximal androgen blockade in advanced prostate cancer. Prostate Suppl. 1994;5:17–22. doi: 10.1002/pros.2990250707. [DOI] [PubMed] [Google Scholar]
  4. Gormley G. J. Role of 5 alpha-reductase inhibitors in the treatment of advanced prostatic carcinoma. Urol Clin North Am. 1991 Feb;18(1):93–98. [PubMed] [Google Scholar]
  5. Gormley G. J., Stoner E., Bruskewitz R. C., Imperato-McGinley J., Walsh P. C., McConnell J. D., Andriole G. L., Geller J., Bracken B. R., Tenover J. S. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med. 1992 Oct 22;327(17):1185–1191. doi: 10.1056/NEJM199210223271701. [DOI] [PubMed] [Google Scholar]
  6. Grigoryev D. N., Kato K., Njar V. C., Long B. J., Ling Y. Z., Wang X., Mohler J., Brodie A. M. Cytochrome P450c17-expressing Escherichia coli as a first-step screening system for 17alpha-hydroxylase-C17,20-lyase inhibitors. Anal Biochem. 1999 Feb 15;267(2):319–330. doi: 10.1006/abio.1998.2993. [DOI] [PubMed] [Google Scholar]
  7. Horoszewicz J. S., Leong S. S., Kawinski E., Karr J. P., Rosenthal H., Chu T. M., Mirand E. A., Murphy G. P. LNCaP model of human prostatic carcinoma. Cancer Res. 1983 Apr;43(4):1809–1818. [PubMed] [Google Scholar]
  8. Jubelirer S. J., Hogan T. High dose ketoconazole for the treatment of hormone refractory metastatic prostate carcinoma: 16 cases and review of the literature. J Urol. 1989 Jul;142(1):89–91. doi: 10.1016/s0022-5347(17)38669-x. [DOI] [PubMed] [Google Scholar]
  9. Klus G. T., Nakamura J., Li J. S., Ling Y. Z., Son C., Kemppainen J. A., Wilson E. M., Brodie A. M. Growth inhibition of human prostate cells in vitro by novel inhibitors of androgen synthesis. Cancer Res. 1996 Nov 1;56(21):4956–4964. [PubMed] [Google Scholar]
  10. Langeler E. G., van Uffelen C. J., Blankenstein M. A., van Steenbrugge G. J., Mulder E. Effect of culture conditions on androgen sensitivity of the human prostatic cancer cell line LNCaP. Prostate. 1993;23(3):213–223. doi: 10.1002/pros.2990230304. [DOI] [PubMed] [Google Scholar]
  11. Ling Y. Z., Li J. S., Liu Y., Kato K., Klus G. T., Brodie A. 17-Imidazolyl, pyrazolyl, and isoxazolyl androstene derivatives. Novel steroidal inhibitors of human cytochrome C17,20-lyase (P450(17 alpha). J Med Chem. 1997 Sep 26;40(20):3297–3304. doi: 10.1021/jm970337k. [DOI] [PubMed] [Google Scholar]
  12. Nakajin S., Hall P. F., Onoda M. Testicular microsomal cytochrome P-450 for C21 steroid side chain cleavage. Spectral and binding studies. J Biol Chem. 1981 Jun 25;256(12):6134–6139. [PubMed] [Google Scholar]
  13. Njar V. C., Kato K., Nnane I. P., Grigoryev D. N., Long B. J., Brodie A. M. Novel 17-azolyl steroids, potent inhibitors of human cytochrome 17 alpha-hydroxylase-C17,20-lyase (P450(17) alpha): potential agents for the treatment of prostate cancer. J Med Chem. 1998 Mar 12;41(6):902–912. doi: 10.1021/jm970568r. [DOI] [PubMed] [Google Scholar]
  14. Pousette A., Carlström K., Henriksson P., Grande M., Stege R. Use of a hormone-sensitive (LNCaP) and a hormone-resistant (LNCaP-r) cell line in prostate cancer research. Prostate. 1997 May 15;31(3):198–203. doi: 10.1002/(sici)1097-0045(19970515)31:3<198::aid-pros9>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  15. Sartor O., Cooper M., Weinberger M., Headlee D., Thibault A., Tompkins A., Steinberg S., Figg W. D., Linehan W. M., Myers C. E. Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer. J Natl Cancer Inst. 1994 Feb 2;86(3):222–227. doi: 10.1093/jnci/86.3.222. [DOI] [PubMed] [Google Scholar]
  16. Sato N., Gleave M. E., Bruchovsky N., Rennie P. S., Beraldi E., Sullivan L. D. A metastatic and androgen-sensitive human prostate cancer model using intraprostatic inoculation of LNCaP cells in SCID mice. Cancer Res. 1997 Apr 15;57(8):1584–1589. [PubMed] [Google Scholar]
  17. Schuurmans A. L., Bolt J., Veldscholte J., Mulder E. Regulation of growth of LNCaP human prostate tumor cells by growth factors and steroid hormones. J Steroid Biochem Mol Biol. 1991;40(1-3):193–197. doi: 10.1016/0960-0760(91)90182-5. [DOI] [PubMed] [Google Scholar]
  18. Shibata A., Ma J., Whittemore A. S. Prostate cancer incidence and mortality in the United States and the United Kingdom. J Natl Cancer Inst. 1998 Aug 19;90(16):1230–1231. doi: 10.1093/jnci/90.16.1230. [DOI] [PubMed] [Google Scholar]
  19. Small E. J., Baron A., Bok R. Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma. Cancer. 1997 Nov 1;80(9):1755–1759. doi: 10.1002/(sici)1097-0142(19971101)80:9<1755::aid-cncr9>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  20. Trachtenberg J., Pont A. Ketoconazole therapy for advanced prostate cancer. Lancet. 1984 Aug 25;2(8400):433–435. doi: 10.1016/s0140-6736(84)92909-x. [DOI] [PubMed] [Google Scholar]
  21. Veldscholte J., Berrevoets C. A., Brinkmann A. O., Grootegoed J. A., Mulder E. Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation. Biochemistry. 1992 Mar 3;31(8):2393–2399. doi: 10.1021/bi00123a026. [DOI] [PubMed] [Google Scholar]
  22. Veldscholte J., Ris-Stalpers C., Kuiper G. G., Jenster G., Berrevoets C., Claassen E., van Rooij H. C., Trapman J., Brinkmann A. O., Mulder E. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun. 1990 Dec 14;173(2):534–540. doi: 10.1016/s0006-291x(05)80067-1. [DOI] [PubMed] [Google Scholar]
  23. Visakorpi T., Hyytinen E., Koivisto P., Tanner M., Keinänen R., Palmberg C., Palotie A., Tammela T., Isola J., Kallioniemi O. P. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet. 1995 Apr;9(4):401–406. doi: 10.1038/ng0495-401. [DOI] [PubMed] [Google Scholar]
  24. Webber M. M., Bello D., Quader S. Immortalized and tumorigenic adult human prostatic epithelial cell lines: characteristics and applications Part 2. Tumorigenic cell lines. Prostate. 1997 Jan 1;30(1):58–64. doi: 10.1002/(sici)1097-0045(19970101)30:1<58::aid-pros9>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  25. Wilding G., Chen M., Gelmann E. P. Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens. Prostate. 1989;14(2):103–115. doi: 10.1002/pros.2990140204. [DOI] [PubMed] [Google Scholar]
  26. Williams G., Kerle D. J., Ware H., Doble A., Dunlop H., Smith C., Allen J., Yeo T., Bloom S. R. Objective responses to ketoconazole therapy in patients with relapsed progressive prostatic cancer. Br J Urol. 1986 Feb;58(1):45–51. doi: 10.1111/j.1464-410x.1986.tb05426.x. [DOI] [PubMed] [Google Scholar]
  27. Wong C., Kelce W. R., Sar M., Wilson E. M. Androgen receptor antagonist versus agonist activities of the fungicide vinclozolin relative to hydroxyflutamide. J Biol Chem. 1995 Aug 25;270(34):19998–20003. doi: 10.1074/jbc.270.34.19998. [DOI] [PubMed] [Google Scholar]
  28. de Launoit Y., Veilleux R., Dufour M., Simard J., Labrie F. Characteristics of the biphasic action of androgens and of the potent antiproliferative effects of the new pure antiestrogen EM-139 on cell cycle kinetic parameters in LNCaP human prostatic cancer cells. Cancer Res. 1991 Oct 1;51(19):5165–5170. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES